Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study

References

• Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009; 360(19): 1989–2003.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2012; 8(1): 42–54.
   Google Scholar
• Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 1984; 27(6): 645–653.
   PubMedGoogle Scholar
• Gruschwitz M, Sepp N, Kofler H, Wick G. Expression of class II-MHC antigens in the dermis of patients with progressive systemic sclerosis. Immunobiology. 1991; 1823–4:234–255.
   PubMedGoogle Scholar
• Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol. 2003; 15(6): 772–777.
   PubMedGoogle Scholar
• Hasegawa M, Sato S. The roles of chemokines in leukocyte recruitment and fibrosis in systemic sclerosis. Front Biosci. 2008; 13:3637–3647.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000; 43(11): 2437–2444.
   PubMed Web of Science ®Google Scholar
• Medsger TA Jr. Classification, purpose. In: Clements PJ, Furst DE. Systemic sclerosis. Philadelphia: Williams & Wilkins; 2004. p. 17–28.
   Google Scholar
• Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005; 35(1): 35–42.
   PubMed Web of Science ®Google Scholar
• Lit LC, Wong CK, Tam LS, Li EK, Lam CW. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis. 2006; 65(2): 209–215.
   PubMedGoogle Scholar
• Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009; 60(10): 3098–3107.
   PubMedGoogle Scholar
• LeRoy EC, Krieg T, Black C, Medsger TAJ, Fleischmajer R, Rowell N, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol. 1988; 15202–205.
   PubMed Web of Science ®Google Scholar
• Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581–90.
   Google Scholar
• Clements P, Lachenbrush P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995; 22:1281–1285.
   PubMed Web of Science ®Google Scholar
• Steen VD, Powell DL, Medsger TAJ. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988; 31:196–203.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Sato S, Kikuchi K, Kawaguchi Y, Fujisaku A, Misaki Y, et al. Evaluation of functional disability using the health assessment questionnaire in Japanese patients with systemic sclerosis. J Rheumatol. 2003; 30(6): 1253–1258.
   PubMedGoogle Scholar
• Chen R, Lowe L, Wilson JD, Crowther E, Tzeggai K, Bishop JE, et al. Simultaneous quantification of six human cytokines in a single sample using microparticle-based flow cytometric technology. Clin Chem. 1999; 45(9): 1693–1694.
   PubMedGoogle Scholar
• Luster AD. Chemokines—chemotactic cytokines that mediate inflammation. N Eng J Med. 1998; 338:436–445.
   PubMed Web of Science ®Google Scholar
• Lee EB, Zhao J, Kim JY, Xiong M, Song YW. Evidence of potential interaction of chemokine genes in susceptibility to systemic sclerosis. Arthritis Rheum. 2007; 56(7): 2443–2448.
   PubMedGoogle Scholar
• Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Takehara K, et al. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol. 2003; 30(7): 1524–1528.
   PubMedGoogle Scholar
• Codullo V, Baldwin HM, Singh MD, Fraser AR, Wilson C, Gilmour A, et al. An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Ann Rheum Dis. 2011; 70(6): 1115–1121.
   PubMedGoogle Scholar
• Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther. 2009; 11(5): R147
   Google Scholar
• Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Pathobiology. 1993; 61:239–246.
   PubMed Web of Science ®Google Scholar
• Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol. 1998; 25(2): 296–301.
   PubMedGoogle Scholar
• Keane MP, Arenberg DA, Lynch JP 3rd, Whyte RI, Iannettoni MD, Burdick MD, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol. 1997; 159(3): 1437–1443.
   PubMedGoogle Scholar
• Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum. 1997; 40:746–751.
   Google Scholar
• Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG, et al. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther. 2009; 11(4): R111
   PubMedGoogle Scholar
• Wolff B, Burns AR, Middleton J, Rot A. Endothelial cell “memory” of inflammatory stimulation: human venular endothelial cells store interleukin 8 in Weibel–Palade bodies. J Exp Med. 1998; 188(9): 1757–1762.
   PubMedGoogle Scholar
• Utgaard JO, Jahnsen FL, Bakka A, Brandtzaeg P, Haraldsen G. Rapid secretion of prestored interleukin 8 from Weibel–Palade bodies of microvascular endothelial cells. J Exp Med. 1998; 188(9): 1751–1756.
   PubMedGoogle Scholar
• Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum. 2001; 44(11): 2665–2678.
   PubMedGoogle Scholar
• Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature. 2000; 404(6776): 407–411.
   PubMedGoogle Scholar
• Distler JH, Jungel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum. 2006; 54(1): 214–225.
   PubMedGoogle Scholar
• Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem. 1996; 271(30): 17779–17784.
   PubMedGoogle Scholar
• Carulli MT, Ong VH, Ponticos M, Shiwen X, Abraham DJ, Black CM, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum. 2005; 52(12): 3772–3782.
   PubMedGoogle Scholar
• Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol. 1999; 117(1): 159–165.
   PubMedGoogle Scholar
• Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis—a longitudinal study. Rheumatology (Oxford). 2008; 47(1): 45–49.
   PubMedGoogle Scholar
• Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol. 2011; 30(2): 231–237.
   PubMedGoogle Scholar
• Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol. 2003; 24(1): 25–29.
   PubMed Web of Science ®Google Scholar
• Distler O, Rinkes B, Hohenleutner U, Scholmerich J, Landthaler M, Lang B, et al. Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis. Rheumatol Int. 1999; 191–2:39–46.
   PubMed Web of Science ®Google Scholar
• Anderegg U, Saalbach A, Haustein UF. Chemokine release from activated human dermal microvascular endothelial cells—implications for the pathophysiology of scleroderma? Arch Dermatol Res. 2000;292(7):341–7.
   Google Scholar
• Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol. 2004; 138(3): 540–546.
   PubMedGoogle Scholar
• Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci. 2004; 35(1): 43–51.
   PubMedGoogle Scholar
• Rabquer BJ, Tsou PS, Hou Y, Thirunavukkarasu E, Haines GK 3rd, Impens AJ, et al. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther. 2011; 13(1): R18
   Google Scholar